Novaliq ’ s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease

Privately-held pharma company Novaliq GmbH said this week that its NovaTears+Omega-3 combo therapy for patients with evaporative dry disease was registered in Europe. The treatment uses Novaliq’s water-free EyeSol drug delivery tech and is available in a multi-dose bottle. The company touted its product as the first eye drop to contain high concentrations of Omega-3 ethyl ester. Get the full story at our sister site, Drug Delivery Business News. The post Novaliq’s NovaTears, Omega-3 combo approved in Europe for evaporative dry eye disease appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Novaliq GmbH Source Type: news